Switching to flavored water or herbal teas may also help reduce the risk of gas
Importantly, future clinical trials should not rely solely on weight-based outcomes
This does not always mean the medication is wrong for the patient
Danuglipron Danuglipron is an oral GLP-1RA developed by Pfizer
When to seek immediate medical attention: Severe abdominal pain that doesn't resolve, possibly radiating to the back (potential pancreatitis) Persistent nausea and vomiting preventing adequate fluid intake (dehydration risk) Signs of allergic reaction: difficulty breathing, swelling of face or throat, severe rash Symptoms of thyroid tumors: lump in neck, hoarseness, difficulty swallowing (rare but serious) Severe hypoglycemia symptoms when used with insulin or sulfonylureas: confusion, seizures, loss of consciousness Changes in vision or eye pain (potential diabetic retinopathy complications, particularly with rapid improvement in blood glucose) Signs of kidney problems: decreased urination, swelling in legs or feet, unusual fatigue Symptoms of gallbladder problems: pain in right or middle upper abdomen, fever, yellowing of skin/eyes These medications carry a boxed warning regarding the risk of thyroid C-cell tumors, based on animal studies
How tough the competition is in the GLP-1 market will also depend on the number of players in the first launch wave
